S. Tang

Preparation and characterization of lung-targeting ceftiofur-loaded gelatin microspheres

Background: Ceftiofur is an effective antibiotic against respiratory infections in livestock. However, ceftiofur concentration that is found in lungs after intravenous injection is not effective. Fortunately, ceftiofur-loaded gelatin microsphere (Cef-MS) enjoys advantages of lung-targeting and can achieve an effective concentration. However, no study has been reported on this modality of drug delivery. Objective: We investigated the properties of this delivery modality—lung targeting ceftiofur-Cef-MSs. Methods: We prepared Cef-MS and investigated drug loading, stability and release characteristics in vitro and studied tissue distribution patterns and potential lung injury in mice. Results: Results showed that the average size and span value are 21.26 μm and 1.07, respectively. Drug loading and loading efficiency were 15.31 and 76.55%, respectively. Cef-MSs were stable in light, heat and humidity, except that agglutinative phenomenon was observed in 90% humidity after 10 days. Cef-MS presented a slower in vitro release pattern compared to ceftiofur. Cef-MS mainly concentrates in lungs after intravenous administration. Furthermore, histopathological studies showed that Cef-MS only induces mild and reversible lung injury and is biologically safe. Conclusion: Cef-MS is a promising alternative form with high lung-targeting properties for the treatment of respiratory infections.

Preparation of a newly formulated long-acting ceftiofur hydrochloride suspension and evaluation of its pharmacokinetics in pigs

A new long-acting ceftiofur hydrochloride preparation was formulated and its physical properties, stability, and pharmacokinetics were investigated in this study. The prepared ceftiofur hydrochloride suspension demonstrated a milk white consistency, was easy to re-disperse and was stable in light, heat and humidity stability tests. Its other physical properties such as flowability, syringeability, settling volume ratio, particle size and distribution were perfectly consistent with the standard of Ministry of Agriculture of the Peoples Republic of China. After intramuscular administration of a single dose in swine (5 mg/kg B.W.), the drug concentration-time data in plasma were well fitted using the two-compartment open model. Compared with the ceftiofur hydrochloride preparation (EXCENEL) from Pfizer, the peak concentration (C(max)) in plasma was decreased by 2.34 times (P < 0.001), the half-life of elimination phase (T(1/2beta)) was 1.65 times longer (P < 0.001), and the therapeutic level of ceftiofur above the lowest effective plasma concentration of 0.2 microg/mL (T > 0.2) was prolonged from 87.20 h to 135.36 h (P < 0.001). The ceftiofur hydrochloride suspension prepared in this study provides therapeutically effective plasma concentrations for a longer duration, which make it more effective and more convenient to use in the treatment of respiratory diseases that require the maintenance of therapeutic plasma concentrations over a long duration.

Nanoemulsion formulation of florfenicol improves bioavailability in pigs

Nanotechnology applications in medicine have seen a tremendous growth in the past decade and are being employed to enhance the stability and bioavailability of lipophilic substances, such as florfenicol. This study aimed to examine the pharmacokinetic properties of the formulated oil-in-water florfenicol-loaded nanoemulsion (FF-NE). FF-NE and florfenicol control (Nuflor) were administered to the pigs at a dose of 20 mg/kg. Nanoemulsion formulation of florfenicol was highly influenced in vivo plasma profile. The in vivo absorption study in pigs indicated that Cmax (14.54 μg/mL) was significantly higher in FF-NE, 3.42 times higher than the marketed formulation. In comparison with the control group, the relative bioavailability of formulated nanoemulsion was up to 134.5%. Assessment of bioequivalence using log-transformed data showed that the 90% confidence intervals (90% CI) of Cmax and AUC₀-∞ were 2.48-4.60 and 1.21-1.72, respectively.

Pharmacokinetics of a novel amoxicillin/colistin suspension after intramuscular administration in pigs

An amoxicillin (AMO) or colistin (COS) oil suspension was developed and corresponding pharmacokinetics studies were conducted in pigs after i.m. injection. The combination product is a white- to cream-colored oil suspension which is easy to be re-dispersed. Settling volume ratio, syringeability and flowability of the product is well consistent with the technical standards set by the Ministry of Agriculture of Peoples Republic of China. Two studies were conducted to investigate the pharmacokinetics of the combination product in swine. First, the pharmacokinetics of the combination product was compared with those of the same products merely removing either AMO or COS. No significant change in the major pharmacokinetic parameters (C(max) , T(max) , MRT, t(1/2λ) , AUC and AUMC) was observed when either component was removed from the combination product, indicating that AMO and COS do not interfere with each other in their absorption and distribution in the tissue when used as a combination. Second, the pharmacokinetics of the combination product was compared with that of their respective single products. It was found that the apparent elimination half-lives (t(1/2λ) ) of AMO and COS in combination product were 6.38 and 8.09 h, which were 2.40 and 2.38 times longer than the single products, respectively. Thus, the novel AMO/COS suspension extended significantly the half-life of both drugs to maintain a longer drug residence time in pigs when compared to their single products.

Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs

A new oil suspension containing 0.15% ivermectin and 15% praziquantel for intramuscular injection was developed, and corresponding pharmacokinetics studies were conducted in swine. The combination product is a white- to cream-colored oil suspension and its physical properties such as settling volume ratio, redispersibility, syringeability and flowability are well consistent with the Technical Standards by the Ministry of Agriculture of the Peoples Republic of China. The pharmacokinetic study consists of two parts. First, the experiments were carried out to compare the pharmacokinetic parameters of the combination product and those same products with praziquantel or ivermectin removed merely. The results showed that no significant change in the major pharmacokinetic parameters (t(1/2z), T(max), C(max), AUC(INF), TimeDur) was observed when either of the component was removed from the combination product, indicating that ivermectin and praziquantel do not interfere with each other when being used together. Second, the pharmacokinetics of the combination product were compared with those of their respective single product. The results showed that the C(max) (15.94 ng/mL) of ivermectin in combination product was 9.01 times higher than the single product, while the AUC(INF) (1925.61 ng h/mL) was 6.02 times higher. Meanwhile, the C(max) (1.48 μg/mL), AUC(INF) (17.08μgh/mL), t(1/2z) (20.25 h), TimeDur3 (42.01 h) and TimeDur4 (16.60 h) of praziquantel in combination product were improved with a factor of 5.48, 13.66, 8.58, 10.10 and 7.31 times when compared with the single product, respectively. Therefore, the efficacy of the combination product was significantly prolonged, especially for praziquantel, so that comprehensive efficacy of controlling parasites sensitive to ivermectin and praziquantel can be achieved with one-single use of it.

Development of a new benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for treatment of heart failure in dogs

The aim of the study was to develop a new chewable benazepril hydrochloride(BH) tablet, investigate its physical properties, and evaluate its bioequivalence with the branded formulation (Fortekor). A corrective agent was included in the formula to improve its palatability and convenience for administration to dogs. The tablet remained stable in light, heat, and humidity tests, and its physical properties such as hardness, uniformity of content, and dissolution rate were highly consistent with the technical standards. After single and repeated administrations to eight beagles and single dose to 14 mongrel dogs (0.5 mg/kg p.o.), plasma BH and its active metabolite, benazeprilat (BZ), were detected. There was no significant difference in the major pharmacokinetic parameters (Cmax , Tmax, and AUC₀₋₂₄) between the two formulations. The 90% confidence intervals calculated for the ratios of area under the time-concentration curve (AUC₀₋₂₄) were 92.4-116.3% for BH and 89.9-102.3% for BZ, within the accepted range for bioequivalence of 80-125%. The results showed our new chewable tablet is bioequivalent to the commercial product and suitable for addition to the benazepril product family for the treatment of heart failure in dogs.